Integrin α 4 β 7

Product Inquiry

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
MibavademabREGN-4461Phase 3 ClinicalLipodystrophy, Congenital Generalized; Lipodystrophy, Familial Partial; Obesity; Lipid Metabolism Disorders
Details
ERX-1000ERX-1000Phase 1 ClinicalERX Pharmaceuticals IncObesity
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyEarliest Brand NameEarliest Approval CountryEarliest IndicationEarliest Approval CompanyEarliest Approval DateIndicationClinical Trial
MetreleptinKTR-103; AC-164594ApprovedAmylin Pharmaceutical, Bristol-Myers Squibb Company, Astrazeneca PlcMetreleptin [SHIONOGI], MyaleptaJapanLipodystrophyShionogi & Co Ltd2013-03-25HIV Infections; Diabetes Mellitus, Type 1; Metabolic Dysfunction-Associated Steatotic Liver Disease; Insulin Resistance; Metabolic Syndrome; Lipodystrophy; Obesity; Lipodystrophy, Congenital Generalized; Lipodystrophy, Familial Partial; Lipomatosis, Multiple Symmetrical; Overweight; Diabetes Mellitus; Hyperlipidemias
Details
  • Product Inquiry
  • Marketed Drug Information
  • Clinical Drug Information
Contact Us

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521

[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland